Skip to main content
Fig. 7 | Journal of Orthopaedic Surgery and Research

Fig. 7

From: Exosomal miR-182 derived from bone marrow mesenchymal stem cells drives carfilzomib resistance of multiple myeloma cells by targeting SOX6

Fig. 7

Loss of SOX6 restrained the biological roles of miR-182 in BMSCs-Exos. A MM.1S and U266 cells were transfected with shNC or shSOX6 for 48 h, then the transfection efficiency was determined by qRT-PCR. MM.1S and U266 cells were treated with Exos−control, Exos−antagomir NC, Exos−miR−182 antagomir and Exos−miR−182 antagomir + shSOX6. B CCK-8 assay was utilized to evaluate MM.1S and U266 cell proliferation. C, D Transwell assay was performed to assess MM.1S and U266 cell C migration and D invasion. E CCK-8 assay was conducted to determine the IC50 of carfilzomib

Back to article page